Differential expression of matrix metalloproteinases in the serum of patients with mucopolysaccharidoses

JIMD Reports

Volumn 3, Issue , 2012, Pages 59-66

  Batzios, Spyros P ^a   Zafeiriou, Dimitrios I ^a   Vargiami, Euthymia ^a   Karakiulakis, George ^a   Papakonstantinou, Eleni ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Consecutive blood sample; Enzyme replacement therapy; Gelatinase activity; Gelatinolytic activity; Lysosomal hydrolase

Indexed keywords

EID: 85006608503     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2011_58     Document Type: Chapter

References (26)

1. Beesley CE, Young EP, Finnegan N et al (2009) Discovery of a new biomarker for the mucopolysaccharidoses (MPS), dipeptidyl peptidase IV (DPP-IV; CD26), by SELDI-TOF mass spectrometry. Mol Genet Metab 96(4):218–224
2. Borkakoti N (1998) Matrix metalloproteases: variations on a theme. Prog Biophys Mol Biol 70(1):73–94
3. Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477(1–2):267–283
4. Castaneda JA, Lim MJ, Cooper JD, Pearce DA (2008) Immune system irregularities in lysosomal storage disorders. Acta Neuropathol 115(2):159–174
5. Clark IM, Swingler TE, Sampieri CL, Edwards DR (2008) The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40(6–7):1362–1378
6. Clarke LA (2008) The mucopolysaccharidoses: a success of molecular medicine. Expert Rev Mol Med 10:e1
7. Di Natale P, Villani GR, Parini R et al (2008) Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease. Biotechnol Appl Biochem 49 (3):219–223
8. Gallegos-Arreola MP, Machorro-Lazo MV, Flores-Martínez SE et al (2000) Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses. Arch Med Res 31(5):505–510
9. Ma X, Tittiger M, Knutsen RH et al (2008) Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice. Mol Genet Metab 94(3):298–304
10. Michelakakis H, Dimitriou E, Tsagaraki S, Giouroukos S, Schulpis K, Bartsocas CS (1995) Lysosomal storage diseases in Greece. Genet Couns 6(1):43–47
11. Muenzer J (2004) The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 144 (5):27–34
12. Mulloy B, Rider CC (2006) Cytokines and proteoglycans: an introductory overview. Biochem Soc Trans 34(3):409–413
13. Mun-Bryce S, Rosenberg GA (1998) Gelatinase B modulates selective opening of the blood–brain barrier during inflammation. Am J Physiol 274(5 Pt 2):1203–1211
14. Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494
15. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421–3452
16. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF (2003) Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 100 (4):1902–1907
17. Papakonstantinou E, Aletras AJ, Glass E et al (2005) Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol 125(4):673–684
18. Proudfoot AE (2006) The biological relevance of chemokine-proteoglycan interactions. Biochem Soc Trans 34(3):422–426
19. Randall DR, Colobong KE, Hemmelgarn H et al (2008) Heparin cofactor II-thrombin complex: a biomarker of MPS disease. Mol Genet Metab 94(4):456–461
20. Richard M, Arfi A, Rhinn H, Gandolphe C, Scherman D (2008) Identification of new markers for neurodegeneration process in the mouse model of Sly disease as revealed by expression profiling of selected genes. J Neurosci Res 86(15):3285–3294
21. Rydlova M, Holubec L Jr, Ludvikova M Jr et al (2008) Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 28(2B):1389–1397
22. Simonaro CM, Haskins ME, Schuchman EH (2001) Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 81(9):1319–1328
23. Simonaro CM, D’Angelo M, Haskins ME, Schuchman EH (2005) Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 57:701–707
24. Simonaro CM, D’Angelo M, He X et al (2008) Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 172(1):112–122
25. Villani GR, Gargiulo N, Faraonio R, Castaldo S, Gonzalez Y, Reyero E, Di Natale P (2007) Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. J Neurosci Res 85(3):612–622
26. Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5(8): 2145–2154